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Abstract
Background: Alterations in gene splicing occur in human sporadic colorectal cancer (CRC) and
may contribute to tumour progression. The K-ras proto-oncogene encodes two splice variants, K-
ras 4A and 4B, and K-ras activating mutations which jointly affect both isoforms are prevalent in
CRC. Past studies have established that splicing of both the K-ras oncogene and proto-oncogene
is altered in CRC in favour of K-ras 4B. The present study addressed whether the K-Ras 4A proto-
oncoprotein can suppress tumour development in the absence of its oncogenic allele, utilising the
ApcMin/+ (Min) mouse that spontaneously develops intestinal tumours that do not harbour K-ras
activating mutations, and the K-rastmΔ4A/tmΔ4A mouse that can express the K-ras 4B splice variant
only. By this means tumorigenesis in the small intestine was compared between ApcMin/+, K-ras+/+
and ApcMin/+, K-rastmΔ4A/tmΔ4A mice that can, and cannot, express the K-ras 4A proto-oncoprotein
respectively.
Methods: The relative levels of expression of the K-ras splice variants in normal small intestine
and small intestinal tumours were quantified by real-time RT-qPCR analysis. Inbred (C57BL/6)
ApcMin/+, K-ras+/+ and ApcMin/+, K-rastmΔ4A/tmΔ4A mice were generated and the genotypes confirmed
by PCR analysis. Survival of stocks was compared by the Mantel-Haenszel test, and tumour number
and area compared by Student's t-test in outwardly healthy mice at approximately 106 and 152 days
of age. DNA sequencing of codons 12, 13 and 61 was performed to confirm the intestinal tumours
did not harbour a K-ras activating mutation.
Results: The K-ras 4A transcript accounted for about 50% of K-ras expressed in the small intestine
of both wild-type and Min mice. Tumours in the small intestine of Min mice showed increased levels
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BMC Gastroenterology 2008, 8:24 http://www.biomedcentral.com/1471-230X/8/24of K-ras 4B transcript expression, but no appreciable change in K-ras 4A transcript levels. No K-
ras activating mutations were detected in 27 intestinal tumours derived from Min and compound
mutant Min mice. K-Ras 4A deficiency did not affect mouse survival, or tumour number, size or
histopathology.
Conclusion: The K-Ras 4A proto-oncoprotein does not exhibit tumour suppressor activity in the
small intestine, even though the K-ras 4A/4B ratio is reduced in adenomas lacking K-ras activating
mutations.
Background
The development of sporadic colorectal cancer (CRC)
involves genetic and epigenetic changes, including allelic
losses in specific chromosomal arms, mutations of onco-
genes, tumour suppressor genes and mismatch repair
genes, micro-satellite instability, and methylation changes
in gene promoters [reviewed [1]]. Additionally, CRC is
frequently associated with altered splicing of tumour sup-
pressor genes, and genes encoding enzymes, growth fac-
tors, cytoskeletal and cell adhesion proteins, hormone
and growth factor receptors, and transcription factors [see
[2-5]]. Importantly, since different splice variants of a
given gene can have different or even antagonistic effects
on diverse cellular functions, including apoptosis, prolif-
eration, differentiation, angiogenesis and cell motility, a
change in the splice variant ratio may actively contribute
to tumour progression. Indeed, positive selection for
splice variants that encode isoforms with a selective
advantage in tumour progression is of potential diagnos-
tic value and could provide therapeutic targets.
Ras proteins are low molecular weight (~21 kD) GTPases
which cycle between the GDP-bound (inactive) and the
GTP-bound (active) state at the plasma membrane, and
thereby regulate cell growth, apoptosis, motility and dif-
ferentiation. K-ras activating point mutations occur in
about 50% of human sporadic CRC cases and act by sta-
bilising the active GTP-bound configuration, and so pro-
mote cellular transformation by constitutive activation of
downstream effector pathways, including Raf kinases,
phosphatidylinositol 3-kinases (PI3-K), and RalGDS fam-
ily members [reviewed [6]]. K-ras activating mutations
play a key role in tumour progression and metastasis in
CRC by regulating angiogenesis and protease expression,
and cell polarity, adhesion and motility [see [7-9]]. The K-
ras gene encodes two splice variants, K-ras 4A and 4B, and
activating mutations that usually arise at codons 12, 13 or
61, jointly affect both isoforms [reviewed [6]]. Impor-
tantly, since K-Ras oncoproteins differentially promote
transformation, cell migration, and anchorage-independ-
ent growth, they most probably act in a cooperative man-
ner to drive neoplastic progression [10]. The ratio of the
K-ras 4A/4B splice variants is reduced in human sporadic
CRC in both primary adenocarcinomas and colon cancer
cell lines that harbour K-ras activating mutations, includ-
ing homozygous mutations [11,12]. Since mutationally
activated K-Ras 4B has an anti-apoptotic action [13,14]
and, unlike K-Ras 4A, can promote cell migration [10],
and K-Ras 4B can drive expression of matrix metallopro-
teinase 2 (MMP-2) which specifically cleaves type IV col-
lagen, and is involved in cell detachment and migration
[15], the altered splicing of the K-ras oncogene in CRC in
favour of K-ras 4B could contribute to neoplastic progres-
sion by enabling the survival of cells with DNA damage
and facilitating tumour invasion and, ultimately, metasta-
sis. Indeed, tumour growth and metastasis in human CRC
is linked with increased expression of MMP-2 [see [7]].
However, the finding that the K-ras 4A/4B ratio is also
reduced in CRC cell lines that lack K-ras activating muta-
tions raises the possibility that a regulated switch in alter-
native splicing of the K-ras proto-oncogene may also have
a causal role in tumour progression [12]. The mechanism
could involve increased expression of MMP-2 (see above),
and/or reduced apoptosis given that the K-Ras 4A proto-
oncoprotein exerts a pro-apoptotic action in mouse intes-
tine following etoposide-induced DNA damage, and evi-
dence that the K-Ras proto-oncoproteins have
antagonistic effects on apoptosis in embryonic stem (ES)
cells: Ras 4A promotes, whereas K-Ras 4B inhibits, apop-
tosis [16]. Further, while K-Ras 4B, and probably K-Ras
4A, promote ES cell differentiation following withdrawal
of leukaemia inhibitory factor [16] it is unlikely they do so
with similar efficiency since the Raf/MAPK pathway regu-
lates stem cell differentiation [reviewed [17]] and K-Ras
4A and 4B differ in their ability to activate Raf-1 [10].
Therefore, in accordance with the 'stem cell model' for
cancer formation we proposed that a change in the ratio
of K-Ras proto-oncoproteins may further contribute to
neoplastic progression by perturbing stem cell differentia-
tion [see [12]]. Thus, altered splicing of the K-ras proto-
oncogene could drive tumour progression in sporadic
CRC by promoting MMP-2 expression, and inappropriate
stem cell survival and self-renewal.
To address the hypothesis that alteration in the ratio of the
K-Ras proto-oncoproteins in favour of K-Ras 4B can affect
tumour formation in the small intestine in the absence of
K-ras activating mutations, K-rastmΔ4A/tmΔ4A mice, which
express the K-ras 4B splice variant only [18], were crossed
with ApcMin/+ (Min) mice. The latter mice harbour a heter-Page 2 of 9
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matous polyposis coli) tumour suppressor gene, and are
predisposed to developing multiple intestinal tumours
initiated by loss of the wild-type Apc allele [reviewed
[19]]. By this means tumorigenesis in the small intestine
was compared between ApcMin/+, K-ras+/+ and ApcMin/+, K-
rastmΔ4A/tmΔ4A mice that can, and cannot, express K-ras 4A
respectively. This approach was selected since K-rastmΔ4A/
tmΔ4A mice are healthy [16,18], intestinal tumours in Min
mice do not harbour K-ras activating mutations [20], and
K-Ras 4A deficiency does not affect K-ras 4B expression in
the small intestine [16] where, importantly, most (> 95%)
intestinal tumours form in Min mice [reviewed [19]].
Thus, the effect of K-Ras 4A on tumorigenesis can be
examined in the absence both of its oncogenic allele and of
alteration in K-ras 4B expression as a consequence of K-
Ras 4A deficiency.
Methods
Mice
All animal work was carried out using procedures
approved by the ethical panel of the University of Edin-
burgh and licensed by the Home Office (Project licence
PPL60/3433). Inbred ApcMin/+ mice (C57BL/6) were
obtained from The Jackson Laboratory (Bar Harbor,
Maine, USA). The K-rastmΔ4A/tmΔ4A mouse has been
reported previously [18]. Since penetrance of the ApcMin
mutation is affected by genetic background, the K-rastmΔ4A
allele on a F1(129/Ola × C57BL/6) background was back-
crossed for a further 8 generations on to the susceptible
C57BL/6 inbred background. Resultant K-rastmΔ4A/tmΔ4A
mice were confirmed as congenic for the C57BL/6 Pla2g2a
allele (Mom-1) by PCR as described previously [21].
Inbred ApcMin/+, K-ras+/+ × Apc+/+, K-rastmΔ4A/tmΔ4A crosses
generated ApcMin/+, K-rastmΔ4A/+ and Apc+/+, K-rastmΔ4A/+
mice. Male ApcMin/+, K-rastmΔ4A/+ mice were crossed with
female Apc+/+, K-rastmΔ4A/+ mice to generate informative
ApcMin/+, K-ras+/+ and ApcMin/+, K-rastmΔ4A/tmΔ4A offspring.
Mice heterozygous for the ApcMin allele were identified by
PCR as described previously that generates a wild-type
(123 bp) and mutant ApcMin (144 bp) band [22]. The K-ras
genotype was determined using primers that amplify K-ras
exon 4A, and primers that identify the mutant K-rastmΔ4A
allele by amplifying the neo cassette which replaces K-ras
exon 4A, that generate 72 bp and 206 bp bands respec-
tively [18]. The genotyping of mice is summarised in
Table 1. Survival curves for ApcMin/+, K-ras+/+ and ApcMin/+,
K-rastmΔ4A/tmΔ4A mice were compared using the Mantel-
Haenszel test [23]. Mice were culled immediately on
showing signs of intestinal neoplasia, including anaemia,
pale feet, hunching and/or swollen abdomen. A small
number of mice (3 male and 4 female ApcMin/+, K-ras+/+
mice, and 4 male and 2 female ApcMin/+, K-rastmΔ4A/tmΔ4A
mice) with rectal prolapse, which were immediately
culled, and also mice randomly withdrawn for tumour
counts were treated as censored observations [23]. Reclas-
sification of mice with prolapse as uncensored observa-
tions did not affect any of the conclusions of the study.
Histology
Mice were killed by CO2 asphyxiation and the small intes-
tine removed, flushed with phosphate buffered saline,
opened lengthwise, and mounted en face. Following fixa-
tion for 4 hours in methacarn (4 volumes methanol, 2
volumes chloroform and 1 volume glacial acetic acid) the
number and area of all visible tumours was scored using a
dissection microscope at 10× magnification.
For examination of tumour pathology, "gut roll" prepara-
tions were made from mice with overt signs of neoplasia
as described above, fixed in 10% buffered formalin, wax
embedded, and stepped serial sections stained with hae-
matoxylin and eosin. Mitotic and apoptotic counts were
defined as the mean number of mitotic or apoptotic fig-
ures in a single high-power (× 400) microscope field
within each of ten adenomas of the small intestine of
comparable size and dysplasia in preparations from five
or six individual mice (of both sexes combined) of each
genotype, counting only intra-epithelial figures and
avoiding debris in glandular lumina and any non-neo-
plastic epithelium on the adenoma surface.
Tumour number, area, and mitotic and apoptotic counts
were compared by Student's t-test.
Table 1: Genotyping litters from ApcMin/+, K-rastmΔ4A/+ × Apc+/+, K-rastmΔ4A/+ crosses to identify informative ApcMin/+, K-ras+/+ and ApcMin/+, 
K-rastmΔ4A/tmΔ4A offspring
Genotype Apc neo K-ras exon 4A
ApcMin/+, K-ras+/+ + (123 bp, 144 bp) - + (72 bp)
ApcMin/+, K-rastmΔ4A/+ + (123 bp, 144 bp) + (206 bp) + (72 bp)
ApcMin/+, K-rastmΔ4A/tmΔ4A + (123 bp, 144 bp) + (206 bp) -
Apc+/+, K-ras+/+ + (123 bp) - + (72 bp)
Apc+/+, K-rastmΔ4A/+ + (123 bp) + (206 bp) + (72 bp)
Apc+/+, K-rastmΔ4A/tmΔ4A + (123 bp) + (206 bp) -
+/- = PCR product present/absent respectively (see Methods)Page 3 of 9
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DNA was prepared from individual tumours dissected
from the small intestine and screened for the presence of
K-ras mutations at codons 12, 13 and 61 as described pre-
viously [20].
Analysis of K-ras 4A and K-ras 4B transcript expression 
levels by quantitative RT-PCR
Normal small intestinal tissue samples and tumours (at
least 2 mm diameter, from mice with overt signs of neo-
plasia as described above, care being taken to avoid
Peyer's patches) were dissected and frozen in "RNA later"
buffer (Sigma) for subsequent RNA extraction. Total RNA
(100 ng) was reverse transcribed in 25 μl volume using the
iTaq SYBR Green RT-PCR kit (Bio-Rad) following the
manufacturer's instructions. All real-time quantitative
reverse transcription polymerase chain reactions (RT-
qPCR) were amplified starting with denaturation at 95°C
for 3 min, then 45 cycles of 95°C for 15 sec and 60°C for
1 min. The following exon-spanning primers were used:
mouse β-actin upstream primer (5'-AAGCTGTGCTATGTT-
GCTCTAGACT-3'), and downstream primer (5'-CACT-
TCATGATGGAATTGAATGTAG-3'); mouse K-ras 4A
upstream primer (5'-CCTGGTAGGGAATAAGTGT-
GATTTG-3'), and downstream primer (5'-GTACTGTCG-
GATCTCTCTCACCAAT-3'); mouse K-ras 4B upstream
primer (5'-GAGTAAAGGACTCTGAAGATGTGCC-3')
located in K-ras exon 3, and downstream primer (5'-
CATCGTCAACACCCTGTCTTGTCTT-3') that spans the
junction of K-ras exon 3 and 4B (specific for the mouse K-
ras 4B transcript). The PCR product sizes derived from K-
ras 4A, K-ras 4B and β-actin transcripts were 185 bp, 158
bp and 148 bp respectively. The specificities of the PCR
reactions were confirmed by dissociation curve analysis
and 2% agarose gel electrophoresis. All PCR products
were analysed when in the exponential phase of PCR
amplification. Quantification of the relative expression
levels of K-ras 4A and K-ras 4B transcripts was performed
using standard curves with normalization against those of
β-actin transcripts from the same sample. The relative val-
ues were corrected for dilution factors and then corrected
for the differences in size of 4A and 4B amplified prod-
ucts. Because the DNA binding affinities of the PCR prim-
ers and the sizes of the amplified products were closely
similar for the K-ras 4A and K-ras 4B PCR reactions, and
the standard curves also showed that the PCR efficiencies
for the K-ras 4A and K-ras 4B PCR reactions were very sim-
ilar at 74.8% and 76.1% respectively, the expression levels
of these two different transcripts, K-ras 4A and K-ras 4B,
can be compared relative to each other, setting the level of
expression of K-ras 4A in wild-type C57BL/6 mouse lung
as an arbitrary value of 1.0.
Results
Both K-ras splice variants are expressed in mouse small
intestine [18,24]. In the present study the relative levels of
the K-ras 4A and 4B transcripts were quantified by real-
time RT-qPCR analysis. Min mice were examined at 8
weeks-old before they showed any visible sign of intesti-
nal tumorigenesis and, for control purposes, comparisons
were made with age-matched wild-type mice. The K-ras
4A/4B transcript ratio did not differ significantly (P =
0.95) between wild-type (1.07 ± 0.09) and Min (1.07 ±
0.15) mice, and in both cases the K-ras 4A transcript
accounted for about 50% of K-ras expressed in the small
intestine (Figure 1).
The reduced K-ras 4A/4B splice variant ratio in sporadic
human CRC involves down-regulation of K-ras 4A expres-
sion [11]. In Min mice (Figure 2), while there was no sig-
nificant difference between K-ras 4A and 4B transcript
Real-time RT-qPCR analysis showing relative expression of the K-ras 4A and 4B tr n cripts (mean ± SD) in small intes-ine (duodenum) from 8 week- ld, inbred (C57BL/6) wild-ype (WT) and ApcMin/+ (M n) mice (6 male mice w re a al s d in ach cohort)Figure 1
Real-time RT-qPCR analysis showing relative expres-
sion of the K-ras 4A and 4B transcripts (mean ± SD) 
in small intestine (duodenum) from 8 week-old, 
inbred (C57BL/6) wild-type (WT) and ApcMin/+ (Min) 
mice (6 male mice were analysed in each cohort). 
Light (stippled) bars, K-ras 4A; dark (hatched) bars, K-ras 4B.
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the small intestine showed significantly reduced levels of
K-ras 4A relative to K-ras 4B transcripts (P = 0.0015). How-
ever, the reduced K-ras 4A/4B splice ratio was due to an
increase in the level of K-ras 4B transcript expression,
while the level of K-ras 4A transcripts was not appreciably
altered. While this provides no support for the hypothesis
that K-ras 4A plays a role in modulating intestinal tumor-
igenesis, it does not exclude this hypothesis, which is wor-
thy of further examination given the high expression
levels and established pro-apoptotic action of K-ras 4A in
mouse intestine and the antagonistic effects of the 4A and
4B isoforms [16]. Therefore, to determine if the K-Ras 4A
proto-oncoprotein can modulate tumorigenesis in the
small intestine comparisons were made between age-
matched ApcMin/+, K-ras+/+ and ApcMin/+, K-rastmΔ4A/tmΔ4A
mice. Since gender may influence tumour development in
the Min mouse [see [25]] males and females were consid-
ered separately. Mice were sampled randomly from the
stock at 106 days when the stock was outwardly healthy,
and at 152 days when 17% (19/112) of the stock had
been either found dead or necessitated necropsy due to
sickness [20% (12/59)ApcMin/+, K-ras+/+ and 13% (7/53)
ApcMin/+, K-rastmΔ4A/tmΔ4A]. Examination of the small intes-
tine revealed a similar overall tumour number, and no dif-
ference in tumour size for both male and female mice at
either time point (Table 2). Histological analysis of intes-
tinal preparations from ApcMin/+, K-ras+/+ (n = 8) and Apc-
Min/+, K-rastmΔ4A/tmΔ4A (n = 7) mice with overt signs of
neoplasia revealed that all tumours from both genotypes
were adenomas of similar, mild to moderate, dysplasia,
with no evidence of invasive carcinoma in any of them.
There was no statistically significant difference between
the genotypes in mitotic counts (ApcMin/+, K-ras+/+: 25.3;
ApcMin/+, K-rastmΔ4A/tmΔ4A: 26.8; P = 0.468) or apoptotic
counts (both genotypes: 2.1; P = 1.0) in the tumours.
Consistent with the tumour data ApcMin/+, K-ras+/+ and Apc-
Min/+, K-rastmΔ4A/tmΔ4A mice exhibited similar survival (Fig-
ure 3) for both males (χ21 = 1.91, P = 0.167) and females
(χ21 = 0.44, P = 0.506).
Previous studies have established that intestinal tumours
from Apc mutant mice, including adenocarcinomas, do
not harbour K-ras activating mutations [20,26,27]. In
confirmation, and to establish this applies in compound
mutant Min mice, K-ras codons 12, 13 and 61 were
sequenced in 27 small intestinal tumours, that included 8
tumours from ApcMin/+, K-ras+/+ mice, 15 tumours from
ApcMin/+, K-rastmΔ4A/+ mice, and 4 tumours from Apc-
Min/+, K-rastmΔ4A/tmΔ4A mice. No tumours were found
to harbour a K-ras activating mutation (data not shown).
Discussion
Because intestinal tumours develop spontaneously in Apc
mutant mice they present a powerful model system to
study factors that modulate intestinal tumour develop-
ment, including genetic modifiers, which may be impor-
tant in the design of potential therapeutic strategies
[reviewed [28]]. To date, inactivating mutations in genes
involved in arachidonic acid and sphingosine metabo-
lism, DNA methylation, and genes encoding the matrix
mellalloproteinase MMP-7, VEGF-A and matricellular
proteins have been found to suppress intestinal tumori-
genesis in Apc mutant mice. Conversely, inactivating
mutations in genes related to genomic stability and DNA
mismatch repair, and genes that regulate PI3-K/AKT sig-
nalling, and proliferation and differentiation in the crypt-
villus axis, promote tumorigenesis [see [19,25,28-38]].
Because homozygosity for the K-ras null allele is embry-
onic lethal [39] nothing is known about the effect of inac-
tivation of the K-ras proto-oncogene on intestinal
Table 2: Tumorigenesis in the small intestine of outwardly healthy ApcMin/+, K-ras+/+ and ApcMin/+, K-rastmΔ4A/tmΔ4A mice
Genotype Sex Mice per cohort Age (days) ± SEM Tumour number ± SEM Tumour area (mm2) ± SEM
Stocks culled at ≅ 106 days
ApcMin/+, K-ras+/+ M 4 108.3 ± 1.0 36.3 ± 7.9a 43.5 ± 9.4i
ApcMin/+, K-ras+/+ F 4 104.5 ± 1.5 59.0 ± 2.9b 74.3 ± 8.8j
ApcMin/+, K-rastmΔ4A/tmΔ4A M 6 107.2 ± 0.5 51.5 ± 16.2c 68.8 ± 23.1k
ApcMin/+, K-rastmΔ4A/tmΔ4A F 4 105.5 ± 0.5 36.5 ± 15.3d 57.0 ± 29.8l
Stocks culled at ≅ 152 days
ApcMin/+, K-ras+/+ M 10 152.0 ± 0.9 56.8 ± 8.8e 131.0 ± 19.6m
ApcMin/+, K-ras+/+ F 4 151.8 ± 1.3 46.3 ± 5.9f 89.8 ± 10.9n
ApcMin/+, K-rastmΔ4A/tmΔ4A M 3 153.3 ± 1.3 35.3 ± 7.5g 99.0 ± 20.0o
ApcMin/+, K-rastmΔ4A/tmΔ4A F 9 151.1 ± 2.8 61.3 ± 9.7h 118.7 ± 22.3p
M, male; F, female. a vs.c P = 0.42;b vs.d P = 0.20; e vs.g P = 0.090;f vs.h P = 0.21; i vs.k P = 0.34;
j vs.l P = 0.60; m vs.o P = 0.28; n vs.p P = 0.27 (Student's t-test in each case).Page 5 of 9
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oncoprotein, whose transcript accounts for some 50% of
K-ras expressed in the small intestine, does not affect
tumour development in the Min mouse intestine where
tumours lack K-ras activating mutations. The result is per-
haps unexpected given that the K-ras proto-oncogene can
promote ES cell differentiation, exert a pro-apoptotic
action in ES cells following DNA damage induced by
etoposide or cisplatin [16,40,41] and, importantly, can
suppress tumour development in the absence [41] as well
as the presence [42] of its oncogenic allele. Moreover, the
K-Ras 4A proto-oncoprotein exerts a pro-apoptotic action
in both ES cells and mouse small intestine following
etoposide-induced DNA damage [16]. The failure of K-Ras
4A to affect tumorigenesis may reflect the fact that K-Ras
4A deficiency does not affect baseline levels of apoptosis
in the crypt [16] and/or abolish completely the apoptotic
response in the small intestine following DNA damage,
but rather it is reduced and delayed, which implies activa-
tion of K-Ras 4A-independent apoptotic pathways. The
complex relationship between apoptosis and cancer
development is highlighted by recent evidence that the
tumour suppressor activity of p53 in radiation-induced
lymphoma is not dependent on its ability to promote
apoptosis and so eliminate mutant cells [43]. Therefore,
the K-Ras 4A-mediated pro-apoptotic response in the
small intestine following etoposide-induced DNA dam-
age could be irrelevant for tumour formation and, indeed,
it does not necessarily follow that K-Ras 4A has a pro-
apoptotic action at physiological levels of DNA damage,
or with other types of DNA damage. Thus, while the pat-
tern of K-ras 4A expression is strongly conserved in human
and mouse tissues [12,18] its role in intestinal homeosta-
sis remains unclear. However, given that K-Ras 4B can
promote ES cell differentiation and suppress mammary
carcinogenesis in the absence of its oncogenic allele
[16,44] it remains to be determined whether K-Ras 4B can
suppress intestinal tumorigenesis. This would necessitate
a comparison between ApcMin/+ mice that can, and cannot,
express K-ras 4B. However, since K-ras is essential for
mouse development [39] and K-ras 4B is the major splice
variant and, unlike K-ras 4A, is expressed ubiquitously
[12,18], it is doubtful that K-Ras 4B-deficient mice would
Survival curve showing ApcMin/+, K-ras+/+ mice [n = 20 males (heavy continuous line), n = 8 females (heavy broken line)] and Apc-Min/+, K-rastmΔ4A/tmΔ4A mice [n = 10 males (light continuous line), n = 16 females (light broken lin )]Figure 3
Survival curve showing ApcMin/+, K-ras+/+ mice [n = 20 males (heavy continuous line), n = 8 females (heavy bro-
ken line)] and ApcMin/+, K-rastmΔ4A/tmΔ4A mice [n = 10 males (light continuous line), n = 16 females (light broken 
line)]. In each case n refers to the number of uncensored observations.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 50 100 150 200 250 300 350 400
Age (days)
K
ap
la
n
-M
ei
er
 s
u
rv
iv
al
 f
u
n
ct
io
nPage 6 of 9
(page number not for citation purposes)
BMC Gastroenterology 2008, 8:24 http://www.biomedcentral.com/1471-230X/8/24be viable, and therefore such a study would require condi-
tional inactivation.
In sporadic CRC the K-ras 4A/4B splice variant ratio is
reduced in colon cancer cell lines, regardless of whether
they harbour K-ras activating mutations [11,12]. Since the
K-ras 4A/4B ratio is reduced in primary CRC tumours [12]
the altered ratio in cell lines, including those that lack K-
ras activating mutations, is more likely to be symptomatic
of the tumours from which they were derived rather than
an in vitro artefact of the growth conditions. While altered
splicing of the K-ras proto-oncogene in favour of K-ras 4B
could, conceivably, modulate tumour progression, and
possibly by effects on MMP-2 expression, apoptosis and/
or differentiation (see Background), the present study
found that alteration in the ratio of the K-Ras proto-onco-
proteins in favour of K-Ras 4B (by targeted deletion of K-
ras exon 4A) does not affect mouse survival or tumour
number, size or histopathology (including mitotic and
apoptotic counts). These observations are unlikely to
reflect the fact that Min mice die before intestinal tumours
can progress, since adenocarcinomas do develop in com-
pound mutant Min mice [see [19,29-31,36]]. They could
relate to the fact that the altered ratio in human CRC
involves not only an decrease in K-ras 4A expression but
also an increase in K-ras 4B expression [11]: indeed, in
Min mouse tumours, K-ras 4B expression is elevated while
K-ras 4A expression is not appreciably altered. K-ras 4B
expression was unaffected in the comparisons shown in
Table 2 and Figure 3 because K-ras 4A deficiency does not
affect K-ras 4B expression in the small intestine [16].
Given that K-ras 4B, unlike K-ras 4A, can promote cell
migration and MMP2 expression [10,15], the possibility
that increased expression of K-ras 4B, with or without
reduced expression of K-ras 4A, is an essential component
for tumour progression in cases that lack K-ras activating
mutations remains to be addressed. Although the present
study establishes that a reduction in the K-ras 4A/4B ratio
does not affect Apc-driven intestinal tumorigenesis per se
the finding that the ratio is reduced in Min adenomas that
lack K-ras activating mutations raises the intriguing possi-
bility that K-ras may have a more widespread role in tum-
origenesis in addition to that in lung, colon and
pancreatic cancers that normally harbour K-ras activating
mutations [reviewed [6]]. Thus, given that K-ras 4A and 4B
are co-expressed widely in mammalian tissues [12,18] it
remains to be determined whether their ratio is altered in
other types of tumours that routinely lack K-ras activating
mutations.
Conclusion
Even though the K-Ras 4A proto-oncoprotein exerts a pro-
apoptotic action in the small intestine following etopo-
side-induced DNA damage, it does not affect tumour
development, albeit when expressed in the absence of its
oncogenic allele.
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